|
Insert Therapeutics - Small Molecule Delivery Programs
Sounds like another promising new method of going straight after the cancer cells! Early days yet, but exciting news, I think.
This method of drug delivery was developed by Mark Davis, a professor of chemical engineering at Caltech who specializes in nanoparticles. His wife was going through breast cancer treatment, and suggested he and the "guys" at Caltech invent something better...It took him 10 years, and his wife has since recovered, but now the Phase I clinical trial is ongoing!
Insert Therapeutics - Small Molecule Delivery Programs
IT-101: CYCLOSERT™-ENHANCED CAMPTOTHECIN
http://www.insertt.com/smallmolecule.html
Preclinical Efficacy of the Camptothecin-Polymer Conjugate IT-101 in Multiple Cancer Models
http://clincancerres.aacrjournals.or...12/5/1606#TBL2
Study of IT-101 in the Treatment of Advanced Solid Tumors
This study is ongoing, but not recruiting participants.
http://clinicaltrials.gov/ct/show/NCT00333502?order=1
__________________
Sept.'99 - Dx.Stage IIIB, IDC ER/PR-, HER2+++ by IHC, confirmed '04 by FISH. Left MRM, AC x's 4, Taxol x's 4, 33 Rads, finishing Tx May 2000. Jan.'01 - local/regional recurrence, Stage IV. Herceptin/Navelbine weekly till NED August 2001, then maintenance Herceptin. Right Mast. April 2002. Local/Regional recurrence April '04, Herceptin plus/minus chemo until May '07. Gemzar added from Feb.'07-April '07; Tykerb/Abraxane until August '07, back on Herceptin plus Taxotere and Xeloda Sept. '07. Stopped T/X Nov. '07, stopped Herceptin Dec. '07, started Avastin/Taxol/Carboplatin Dec. '07. Progression in chest skin, stopped TAC March '03, started radiation.
Herceptin has served as the "Backbone" of my treatment strategy for over 6 years, giving me great quality of life. In 2005, I was privileged to participate in the University of Washington/Seattle HER2 Vaccine Trial.
|
Linear Mode
